Maraviroc

Information about Maraviroc

Maraviroc is a chemokine co-receptor 5 (CCR5) antagonist, the first of a new class of agents active against the human immunodeficiency virus (HIV) and the acquired immunodeficiency syndrome (AIDS).

FDA approval information for Maraviroc

Maraviroc was approved for use in the United States in 2007 and has had limited use.

Liver safety of Maraviroc

Maraviroc has been associated with elevations in serum aminotransferase levels and to several cases of acute, clinically apparent liver injury.

Mechanism of action of Maraviroc

Maraviroc (mar" a vir' ok) is relatively new antiretroviral drug that targets one of the receptors for HIV that is present on the surface of lymphocytes. Maraviroc interrupts the binding of HIV to target cells by blocking the chemokine coreceptor 5 (CCR5), a necessary receptor in the uptake of HIV into cells. Maraviroc has both in vitro and in vivo activity against HIV and several randomized controlled trials have shown that it leads to significant decline in HIV RNA levels and rises in peripheral [[CD4 T cell counts]. Maraviroc was given accelerated approval for use in HIV infection in the United States in 2007 and is currently used in a relatively small proportion of antiretroviral regimens, being recommended largely for HIV-treatment experienced adult patients with CCR5-tropic strains of HIV.

Dosage and administration for Maraviroc

Maraviroc is available as 150 and 300 mg tablets under the brand name Selzentry. The recommended dose is 150 to 600 mg twice daily in combination with other classes of antiretroviral agents. Common side effects include cough, fever, rash and dizziness.

Antiviral agents

Drugs for HIV Infection, in the Subclass Antiretroviral Agents

• Fusion Inhibitors (HIV)
  • Enfuvirtide, Maraviroc

• Integrase Inhibitors (HIV)
  • Dolutegravir, Elvitegravir, Raltegravir

• Monoclonal Antibodies
  • Ibalizumab

• Nonnucleoside Reverse Transcriptase Inhibitors (HIV)
  • Delavirdine, Efavirenz, Etravirine, Nevirapine, Rilpivirine

• Nucleoside Analogues (HIV)
  • Abacavir, Didanosine, Emtricitabine, Lamivudine, Stavudine, Tenofovir, Zidovudine

• Protease Inhibitors (HIV)
  • Amprenavir, Atazanavir, Darunavir, Fosamprenavir, Indinavir, Lopinavir, Nelfinavir,Ritonavir, Saquinavir, Tipranavir

Drugs for Hepatitis B

• • Alpha Interferon, Adefovir, Emtricitabine, Entecavir, Lamivudine, Telbivudine, Tenofovir

Drugs for Hepatitis C

• Interferon Based Therapies
  • Alpha Interferon and Peginterferon, Ribavirin

HCV NS5A Inhibitors

• Daclatasvir, Elbasvir, Ledipasvir, Ombitasvir, Pibrentasvir, Velpatasvir

HCV NS5B (Polymerase) Inhibitors

• Dasabuvir, Sofosbuvir

HCV Protease Inhibitors

• Asunaprevir, Boceprevir, Glecaprevir, Grazoprevir, Paritaprevir, Simeprevir, Telaprevir, Voxilaprevir

Combination Therapies

• Epclusa, Harvoni, Mavyret, Technive, Viekira Pak, Vosevi, Zepatier

Drugs for Herpes Virus Infections (HSV, CMV, others)

• Acyclovir, Cidofovir, Famciclovir, Foscarnet, Ganciclovir, Valacyclovir, Valganciclovir

Drugs for Influenza

• Amantadine, Oseltamivir, Peramivir, Rimantadine, Zanamivir

• Dailymed label info on Maraviroc
• FDA Maraviroc

• 

  Chemical structure of Maraviroc

• 

  Ball-and-stick model of Maraviroc